A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient must have a clinical diagnosis of acute cortical ischemic stroke.
Patient must be randomized into the study within six hours after the initial onset of stroke symptoms.
Patient must have a measurable focal neurological deficit for a minimum duration of 60 minutes.
Patient must have a CT or MRI examination compatible with the clinical diagnosis of acute ischemic stroke.
Patient must have had a pre-stroke mRS scale score of 0 or 1.
Other inclusion criteria as specified in the study protocol.
Patient must not have a body weight of more than 125 kg.
Patient must not have a CT and/or MRI with evidence of a non-ischemic mechanism, subarachnoid hemorrhage, or primary intracerebral and/or intraventricular hemorrhage.
Patient must not have all three of the following findings:
reduced level of consciousness (has score of greater than or equal to two on NIHSS Question 1a)
forced eye deviation or total gaze paresis (has score of 2 on NIHSS Question 2) and
dense hemiplegia (no movement) of upper and lower extremities (i.e., has score of 4 on NIHSS Question 5 regarding motor arm and has score of 4 on NIHSS Question 6 regarding motor leg).
Patient must not have neurological signs and symptoms that are rapidly improving.
Patient must not have a severe coexisting or terminal systemic disease.
Patient must not be pregnant or lactating.
Patient must not have impaired hepatic function; bilirubin greater than 2 mg/dL and or ascites.
Patient must not have impaired renal function; serum creatinine greater than 2 mg/dL.
Patient must not have congestive heart failure.
Patient must not have a baseline ECG showing a PR interval greater than 200 milliseconds, or a corrected QT interval of greater than 480 milliseconds, or a history of ventricular arrhythmias, or a Mobitz Type 1 or greater AV block.
Patient must not have other exclusion criteria as specified in the study protocol.